197 completed, 39 unknown, 37 terminated, 21 recruiting. 96 Phase 3, 79 Phase 2, 77 Phase 4, 46 Not applicable, 27 Phase 1.
Follow Enoxaparin: new trials by email Literature Review of Enoxaparin trials Research Report on Enoxaparin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP). Enoxaparin - Venous Thromboembolism (VTE) | Phase 3 | Not yet recruiting | Johns Hopkins All Children's Hospital | 802 | 2027-04-15 | 2026-05-26 |
| Efficacy of Progesterone and Low Molecular Weight Heparin in Recurrent Miscarriages Vaginal micronized progesterone, Enoxaparin (LMWH) - Pregnancy Loss, Pregnancy Loss, Early | Phase 3 | Not yet recruiting | General University Hospital, Prague | 264 | 2026-12-01 | 2026-09-09 |
| Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty Apixaban, Rivaroxaban, Enoxaparin (LMWH) - Total Knee Arthroplasty, Venous Thromboembolism | Not applicable | Recruiting | Military Hospital of Tunis | 138 | 2026-09-15 | 2026-10-16 |
| The OAT Trail: The Obesity Anti-Coagulation Thromboprophylaxis Trial. Anti-Xa Activity Monitoring, Tinzaparin (Leo), enoxaparin - Bariatric Surgery, Anti-Xa Activity | Not applicable | Not yet recruiting | University College Dublin | 180 | 2026-08-01 | 2026-05-18 |
| Prophylactic Anticoagulation for Central Venous Line Insertion in Critically Ill Children Enoxaparin - Prophylactic, Anticoagulation | Not applicable | Recruiting | Menoufia University | 40 | 2026-08-01 | 2026-10-07 |
| Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis Apixaban, Enoxaparin - Postpartum, DVT Prophylaxis | Not applicable | Not yet recruiting | Ron Beloosesky MD | 150 | 2026-07-01 | 2026-07-21 |
| The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity Aspirin, Low-molecular-weight heparin - Venous Thromboembolism, Postpartum Period | Phase 3 | Recruiting | University of Calgary | 8805 | 2026-06-04 | 2026-07-27 |
| STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism Anticoagulants, Thrombolytic Agents, Mechanical Thrombectomy Devices - Pulmonary Embolism, Venous Thromboembolism | Not yet recruiting | Nanjing First Hospital, Nanjing Medical University | 1300 | 2026-06-01 | 2026-05-22 | |
| Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar With That From Clexane Enoxaparin 40 Mg/0.4 mL Injectable Solution - Healthy Participants Study, The Focus of the Study is to Determine the Comparative Pharmacodynamic of Enoxaparin Sodium With That of Clexane in Healthy Human Participants | Phase 1 | Not yet recruiting | Egyptian International Pharmaceutical Industries Co | 26 | 2026-04-30 | 2026-04-08 |
| Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial Enoxaparin standard dose, Enoxaparin intermediate dose - Severe Trauma Patient, Venous Thromboembolism | Not applicable | Not yet recruiting | University Hospital, Grenoble | 540 | 2026-04-01 | 2026-04-29 |
| Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction Enoxaparin, Standard Management - Intrauterine Growth Restriction | Not applicable | Not yet recruiting | Muhammad Aamir Latif | 108 | 2026-04-01 | 2026-03-10 |
| A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants Andexanet alfa, Rivaroxaban, Apixaban - Healthy Participants | Phase 1 | Completed | AstraZeneca | 191 | 2026-01-19 | 2026-07-09 |
| Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention rivaroxaban and ASA, Low-molecular weight heparin, Fondaparinux - Hip Fracture Surgery, Cardiovascular Prevention | Phase 3 | Not yet recruiting | McMaster University | 100 | 2025-12-01 | 2025-11-14 |
| Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis Outcomes Rivaroxaban, Enoxaparin 40 mg - Postpartum Period, Cesarean Section Surgery | Not applicable | Recruiting | Wolfson Medical Center | 62 | 2025-12-01 | 2026-09-15 |
| Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention rivaroxaban (10mg), Enoxaparin 40 mg SC - Deep Venous Thromboses, Laparotomy Patients | Phase 4 | Recruiting | Mayo Hospital Lahore | 212 | 2025-10-10 | 2025-11-21 |
| Apixaban or Enoxaparin After Head and Neck Cancer Surgery Enoxaparin, Apixaban - Venous Thromboembolism, Head and Neck Cancer | Phase 4 | Recruiting | Kiranya Arnold | 76 | 2025-10-01 | 2025-10-08 |
| A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA SRSD107, enoxaparin - Venous Thromboembolism | Phase 2 | Recruiting | Sirius Therapeutics Co., Ltd. | 450 | 2025-09-16 | 2026-01-15 |
| Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome Edoxaban 60 mg, Enoxaparin 40 mg - Nephrotic Syndrome, Hypoalbuminemia | Not applicable | Not yet recruiting | Peking University People's Hospital | 60 | 2025-09-01 | 2025-08-11 |
| REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults REGN7508, Apixaban, Enoxaparin - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 2000 | 2025-06-25 | 2026-10-08 |
| Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis Dabigatran, Enoxaparin - Portal Vein Thrombosis, Liver Cirrhosis | Phase 2 / Phase 3 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 120 | 2025-01-31 | 2025-02-10 |
Showing 20 of 322. Sign in to see all of them.
Venous Thromboembolism (88) · Venous Thrombosis (76) · Pulmonary Embolism (43) · Thrombosis (33) · COVID-19 (25) · Thromboembolism (20) · Hemorrhage (16) · Myocardial Infarction (10) · Acute Coronary Syndrome (9) · Neoplasms (9) · Hemostatic Disorders (8) · Wounds and Injuries (8) · Abortion, Habitual (6) · Angina, Unstable (6) · Critical Illness (6)
Sanofi (14) · Bayer (13) · Boehringer Ingelheim (8) · Bristol-Myers Squibb (8) · University of Utah (7) · Daiichi Sankyo (5) · Ain Shams University (4) · Les Laboratoires des Médicaments Stériles (4) · McMaster University (4) · Assistance Publique - Hôpitaux de Paris (3) · Astellas Pharma Inc (3) · Brigham and Women's Hospital (3) · Centre Hospitalier Universitaire de Saint Etienne (3) · Massachusetts General Hospital (3) · Oregon Health and Science University (3)
United States (115) · Canada (55) · France (42) · Italy (40) · Poland (40) · Germany (35) · Spain (34) · Denmark (31) · Israel (31) · Belgium (29) · Russia (29) · Brazil (28) · Australia (27) · Austria (27) · United Kingdom (27)
Alexander Turpie, MD (2) · Christopher Puccini, MD (2) · Jeffrey Zwicker, MD (2) · Leslie Skeith, MD (2) · Marc Rodger, MD (2)
PMID 35244208, PMID 33502773, PMID 33779986, PMID 32358837, PMID 35570249, PMID 36413425, PMID 37591523, PMID 22429800, PMID 22709460, PMID 28617144, PMID 28762617, PMID 32407672, PMID 33337539, PMID 21856483, PMID 22863355, PMID 22995531, PMID 23279103, PMID 26578849, PMID 29452956, PMID 29649055, PMID 32657973, PMID 33086312, PMID 37489818, PMID 37794281, PMID 41218619, PMID 10453824, PMID 10546719, PMID 10647756, PMID 10648016, PMID 10661066, PMID 10737280, PMID 10927736, PMID 10963635, PMID 11011804, PMID 11156876, PMID 11157643, PMID 11181470, PMID 11287711, PMID 11867132, PMID 12090565, PMID 12147872, PMID 12387283, PMID 12393647, PMID 12475453, PMID 12575964, PMID 12586125, PMID 12644342, PMID 12709915, PMID 12719198, PMID 12763484
2016 (4), 2004 (3), 2008 (3), 2015 (3), 2025 (3), 2005 (2), 2017 (2), 2018 (2), 1OT2HL156812-01 (1), 2014 (1), 2019 (1), 2023 (1), R01HD106326 (1), R21HD089131 (1), R34HL135226 (1)